Lyell Immunopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $<0.1 | $0.1 | $0.1 | $84.7 | $10.7 |
| Operating income | -$269.4 | -$358.8 | -$247.0 | -$187.1 | -$214.8 |
| Net income | -$274.4 | -$343.0 | -$234.6 | -$183.1 | -$250.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$150.8 | -$162.9 | -$166.4 | -$193.8 | -$191.8 |
| Share repurchases | — | — | — | $0.0 | $0.0 |
Shares outstanding 23.3M · Free float 48.1%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.